

Emphysema Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2020-2030F

Market Report | 2025-03-24 | 182 pages | TechSci Research

## **AVAILABLE LICENSES:**

- Single User License \$4500.00
- Multi-User License \$5500.00
- Custom Research License \$8000.00

# **Report description:**

Global Emphysema Treatment Market was valued at USD 4.47 Billion in 2024 and is expected to reach USD 6.36 Billion in the forecast period with a CAGR of 6.02% through 2030. The global emphysema treatment market is witnessing steady growth, driven by advancements in medical technology and increasing awareness about chronic respiratory diseases. Emphysema, a progressive lung condition often linked to smoking and environmental pollutants, has seen a rise in prevalence, prompting demand for effective treatment options. Pharmaceutical and medical device companies are actively developing innovative therapies, including long-acting bronchodilators, biologics, and minimally invasive procedures like lung volume reduction surgery (LVRS) and endobronchial valve implantation. The shift toward personalized treatment strategies is improving patient outcomes by tailoring interventions based on disease severity and individual response to therapy. The expansion of home healthcare solutions, including portable oxygen therapy devices and digital respiratory monitoring tools, is enhancing disease management and supporting market growth.

Ongoing research into regenerative medicine and gene-based therapies is transforming the treatment landscape by exploring potential disease-modifying solutions. The development of targeted anti-inflammatory and regenerative therapies aims to slow disease progression and improve lung function. Biopharmaceutical companies are focusing on monoclonal antibodies and stem

cell therapies as emerging treatment avenues. The integration of artificial intelligence (AI) in diagnostics and disease monitoring is enabling early detection and more precise intervention, reducing complications. Companies are investing in pipeline expansion through collaborations and clinical trials, with an emphasis on improving treatment efficacy and reducing adverse effects. The emphasis on combination therapies, incorporating bronchodilators, anti-inflammatory drugs, and pulmonary rehabilitation programs, is enhancing comprehensive disease management and driving product innovation.

#### Key Market Drivers

#### Advancements in Medical Technology

Advancements in medical technology are significantly enhancing the global emphysema treatment market. Emphysema, a debilitating form of chronic obstructive pulmonary disease (COPD), has historically been challenging to manage. However, recent technological breakthroughs are transforming emphysema care.

Minimally invasive procedures, such as bronchoscopic lung volume reduction (BLVR), have become pivotal in emphysema treatment. BLVR involves the insertion of devices like endobronchial valves to occlude diseased lung regions, thereby improving respiratory function. Clinical studies have demonstrated that BLVR can enhance lung performance and quality of life in selected patients. For instance, research indicates that BLVR procedures have shown promising outcomes in improving lung function and exercise capacity among patients with advanced emphysema.

The development of biologics and targeted therapies marks another significant advancement in emphysema management. These treatments aim at specific molecular pathways that contribute to disease progression, potentially decelerating emphysema's advancement and enhancing pulmonary function. This targeted approach offers a more effective and less invasive alternative to traditional therapies.

## Key Market Challenges

## High Treatment Costs

High treatment costs are a significant barrier hindering the advancement of the Global Emphysema Treatment Market. Emphysema, a debilitating chronic obstructive pulmonary disease (COPD), affects millions of individuals worldwide, and managing this condition can be financially burdensome for both patients and healthcare systems.

The development of innovative emphysema treatments, such as bronchoscopic lung volume reduction (BLVR) procedures and targeted biologics, has offered new hope to patients by providing potentially more effective and less invasive options. However, these cutting-edge treatments often come with a hefty price tag.

For many emphysema patients, the high cost of treatment represents a substantial financial barrier. Coping with the financial burden of these therapies can be overwhelming, particularly for those without comprehensive health insurance coverage. High deductibles, copayments, and out-of-pocket expenses can strain patients' finances and limit their access to essential treatments. Additionally, emphysema is a chronic condition that often requires ongoing care, including medications, regular check-ups, and pulmonary rehabilitation. These long-term expenses further compound the financial challenges faced by patients, potentially forcing them to make difficult choices between healthcare and other essential needs.

The burden of high treatment costs also extends to healthcare systems and governments. As the prevalence of emphysema continues to rise, the strain on healthcare budgets becomes more pronounced. The cost of providing advanced treatments and therapies can lead to allocation challenges, diverting resources from other critical healthcare needs.

#### Key Market Trends

# Adoption of Minimally Invasive Procedures

The adoption of minimally invasive procedures is playing a pivotal role in boosting the Global Emphysema Treatment Market. Emphysema, a progressive lung condition characterized by the destruction of lung tissue, has traditionally been associated with invasive surgical treatments or long-term medication. However, recent advancements in medical technology have led to the development and widespread adoption of minimally invasive procedures, offering a paradigm shift in the way emphysema is treated.

One of the most significant contributors to the growth of minimally invasive procedures is the emergence of bronchoscopic lung volume reduction (BLVR) techniques. BLVR involves the insertion of small devices or materials into the airways to block or reduce airflow to damaged lung areas. This procedure aims to improve lung function and alleviate symptoms without the need for open surgery. Patients benefit from shorter hospital stays, faster recovery times, and reduced risk of complications compared to

traditional surgical approaches.

The appeal of minimally invasive procedures goes beyond their effectiveness; it lies in their patient-centric approach. Patients are more inclined to opt for less invasive treatments that offer quicker recovery times and a lower risk of complications. As a result, healthcare providers increasingly recommend and perform BLVR and other minimally invasive procedures, meeting the preferences and expectations of patients.

Moreover, the adoption of minimally invasive procedures aligns with the broader trend in healthcare toward value-based care and cost-effectiveness. These procedures typically lead to reduced healthcare costs due to shorter hospital stays and less post-operative care, benefiting both patients and healthcare systems.

Key Market Players

- Icure Pharmaceuticals Inc.

- AstraZeneca Plc.

- Teva Pharmaceuticals Industries Ltd.

- -[]Novartis AG
- GlaxoSmithKline Plc.
- Hikma Pharmaceuticals Plc
- Boehringer Ingelheim International GmbH
- Mylan N.V.

-∏Pfizer Inc.

Orion Corporation

Report Scope:

In this report, the Global Emphysema Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

- Emphysema Treatment Market, By Treatment:

- o Smoking Cessation
- o Bronchodilators
- o Steroids
- o Leukotriene Modifiers
- o Supplemental Oxygen
- o Antibiotics
- o Gene Therapy
- o Surgery Transplant
- o Other Treatments
- Emphysema Treatment Market, By Distribution Channel:
- o Hospital Pharmacy
- o Retail Pharmacy
- o Other Distribution Channels
- Emphysema Treatment Market, By End-User:
- o Hospitals & Clinics
- o Ambulatory Surgical Centers
- o Others
- Emphysema Treatment Market, By Region:
- o North America
- United States
- 🛛 Canada
- 🛛 Mexico
- o Europe
- 🛛 France

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

United Kingdom [] Italy □ Germany Spain o Asia-Pacific 🗆 China 🛛 India 🛛 Japan 🛛 Australia □ South Korea o South America 🛛 Brazil Argentina 🛛 Colombia o Middle East & Africa □ South Africa 🛛 Saudi Arabia 🛛 UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Emphysema Treatment Market. Available Customizations:

Global Emphysema Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

**Company Information** 

- Detailed analysis and profiling of additional market players (up to five).

# **Table of Contents:**

- 1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
- 2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
- 3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

- 4. Global Emphysema Treatment Market Outlook
- 4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.2. Market Share & Forecast
- 4.2.1. By Treatment (Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments)
- 4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
- 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
- 4.2.4. By Region
- 4.2.5. By Company (2024)
- 4.3. Market Map
- 4.3.1. By Treatment
- 4.3.2. By Distribution Channel
- 4.3.3. By End-User
- 4.3.4. By Region
- 5. Asia Pacific Emphysema Treatment Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Treatment
- 5.2.2. By Distribution Channel
- 5.2.3. By End-User
- 5.2.4. By Country
- 5.3. Asia Pacific: Country Analysis
- 5.3.1. China Emphysema Treatment Market Outlook
- 5.3.1.1. Market Size & Forecast
- 5.3.1.1.1. By Value
- 5.3.1.2. Market Share & Forecast
- 5.3.1.2.1. By Treatment
- 5.3.1.2.2. By Distribution Channel
- 5.3.1.2.3. By End-User
- 5.3.2. India Emphysema Treatment Market Outlook
- 5.3.2.1. Market Size & Forecast
- 5.3.2.1.1. By Value
- 5.3.2.2. Market Share & Forecast
- 5.3.2.2.1. By Treatment
- 5.3.2.2.2. By Distribution Channel
- 5.3.2.2.3. By End-User
- 5.3.3. Australia Emphysema Treatment Market Outlook
- 5.3.3.1. Market Size & Forecast
- 5.3.3.1.1. By Value
- 5.3.3.2. Market Share & Forecast
- 5.3.3.2.1. By Treatment
- 5.3.3.2.2. By Distribution Channel
- 5.3.3.2.3. By End-User
- 5.3.4. Japan Emphysema Treatment Market Outlook
- 5.3.4.1. Market Size & Forecast

5.3.4.1.1. By Value 5.3.4.2. Market Share & Forecast 5.3.4.2.1. By Treatment 5.3.4.2.2. By Distribution Channel 5.3.4.2.3. By End-User 5.3.5. South Korea Emphysema Treatment Market Outlook 5.3.5.1. Market Size & Forecast 5.3.5.1.1. By Value 5.3.5.2. Market Share & Forecast 5.3.5.2.1. By Treatment 5.3.5.2.2. By Distribution Channel 5.3.5.2.3. By End-User 6. Europe Emphysema Treatment Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Treatment 6.2.2. By Distribution Channel 6.2.3. By End-User 6.2.4. By Country 6.3. Europe: Country Analysis 6.3.1. France Emphysema Treatment Market Outlook 6.3.1.1. Market Size & Forecast 6.3.1.1.1. By Value 6.3.1.2. Market Share & Forecast 6.3.1.2.1. By Treatment 6.3.1.2.2. By Distribution Channel 6.3.1.2.3. By End-User 6.3.2. Germany Emphysema Treatment Market Outlook 6.3.2.1. Market Size & Forecast 6.3.2.1.1. Bv Value 6.3.2.2. Market Share & Forecast 6.3.2.2.1. By Treatment 6.3.2.2.2. By Distribution Channel 6.3.2.2.3. By End-User 6.3.3. Spain Emphysema Treatment Market Outlook 6.3.3.1. Market Size & Forecast 6.3.3.1.1. By Value 6.3.3.2. Market Share & Forecast 6.3.3.2.1. By Treatment 6.3.3.2.2. By Distribution Channel 6.3.3.2.3. By End-User 6.3.4. Italy Emphysema Treatment Market Outlook 6.3.4.1. Market Size & Forecast 6.3.4.1.1. By Value 6.3.4.2. Market Share & Forecast 6.3.4.2.1. By Treatment

- 6.3.4.2.2. By Distribution Channel
- 6.3.4.2.3. By End-User
- 6.3.5. United Kingdom Emphysema Treatment Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.1.1. By Value
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Treatment
- 6.3.5.2.2. By Distribution Channel
- 6.3.5.2.3. By End-User
- 7. North America Emphysema Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Treatment
- 7.2.2. By Distribution Channel
- 7.2.3. By End-User
- 7.2.4. By Country
- 7.3. North America: Country Analysis
- 7.3.1. United States Emphysema Treatment Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Treatment
- 7.3.1.2.2. By Distribution Channel
- 7.3.1.2.3. By End-User
- 7.3.2. Mexico Emphysema Treatment Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Treatment
- 7.3.2.2.2. By Distribution Channel
- 7.3.2.2.3. By End-User
- 7.3.3. Canada Emphysema Treatment Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Treatment
- 7.3.3.2.2. By Distribution Channel
- 7.3.3.2.3. By End-User
- 8. South America Emphysema Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Treatment
- 8.2.2. By Distribution Channel
- 8.2.3. By End-User
- 8.2.4. By Country

8.3. South America: Country Analysis 8.3.1. Brazil Emphysema Treatment Market Outlook 8.3.1.1. Market Size & Forecast By Value 8.3.1.1.1. 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Treatment 8.3.1.2.2. By Distribution Channel 8.3.1.2.3. By End-User 8.3.2. Argentina Emphysema Treatment Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Treatment 8.3.2.2.2. By Distribution Channel 8.3.2.2.3. By End-User 8.3.3. Colombia Emphysema Treatment Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Treatment 8.3.3.2.2. By Distribution Channel 8.3.3.2.3. By End-User 9. Middle East and Africa Emphysema Treatment Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Treatment 9.2.2. By Distribution Channel 9.2.3. By End-User 9.2.4. By Country 9.3. MEA: Country Analysis 9.3.1. South Africa Emphysema Treatment Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Treatment 9.3.1.2.2. By Distribution Channel 9.3.1.2.3. By End-User 9.3.2. Saudi Arabia Emphysema Treatment Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Treatment 9.3.2.2.2. By Distribution Channel By End-User 9.3.2.2.3. 9.3.3. UAE Emphysema Treatment Market Outlook 9.3.3.1. Market Size & Forecast

- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Treatment
- 9.3.3.2.2. By Distribution Channel
- 9.3.3.2.3. By End-User
- 10. Market Dynamics
- 10.1. Drivers
- 10.2. Challenges
- 11. Market Trends & Developments
- 11.1. Recent Developments
- 11.2. Product Launches
- 11.3. Mergers & Acquisitions
- 12. Global Emphysema Treatment Market: SWOT Analysis
- 13. Porter's Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Product
- 14. Competitive Landscape
- 14.1. Icure Pharmaceuticals Inc.
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Current Capacity Analysis
- 14.1.5. Financials (In case of listed)
- 14.1.6. Recent Developments
- 14.1.7. SWOT Analysis
- 14.2. AstraZeneca Plc.
- 14.3. Teva Pharmaceuticals Industries Ltd.
- 14.4. Novartis AG
- 14.5. GlaxoSmithKline Plc.
- 14.6. Hikma Pharmaceuticals Plc
- 14.7. Boehringer Ingelheim International GmbH
- 14.8. Mylan N.V.
- 14.9. Pfizer Inc.
- 14.10. Orion Corporation
- 15. Strategic Recommendations
- 16. About Us & Disclaimer

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com



Emphysema Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2020-2030F

Market Report | 2025-03-24 | 182 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- □ Send as a scanned email to support@scotts-international.com

#### **ORDER FORM:**

Select license	License		Price
	Single User License		\$4500.00
	Multi-User License		\$5500.00
	Custom Research License		\$8000.00
		VAT	
		Total	

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		

Company Name*	EU Vat / Tax ID / NIP number*	
Address*	City*	
Zip Code*	Country*	
	Date	2025-06-26
	Signature	